Clinical trials – Page 3
-
NewsCovid-19 is forcing pharma to rethink clinical trials
Drug trials have become a casualty of Covid-19, but the pandemic is also prompting change
-
OpinionHopes and fears for remdesivir
Available resources for testing coronavirus treatments need to be used wisely
-
OpinionDoes the drug work, or not?
Coronavirus trials reveal the murky reality of disentangling compounds’ effects on human biology
-
-
OpinionVaccine development against the clock
How long will it take to develop a coronavirus vaccine and why is it so hard?
-
BusinessCan existing drugs slow Covid-19?
The fastest route to treatments may be to repurpose existing drugs – if they work
-
-
BusinessSixth in a line of Alzheimer’s drugs fails in trials
Treatments designed to stop amyloid peptide formation all seem to cause cognitive impairment rather than prevent it
-
OpinionAre new drugs better than existing ones?
Should companies be made to change the way they run clinical trials?
-
BusinessCleaning up clinical trials
Campaigns to enforce complete and correct reporting of trial data are beginning to take hold
-
NewsTracker to name and shame for failure to report clinical trial results
Developers of online tool hope that it will improve accountability
-
BusinessCall for overhaul of EU rules on GMO clinical trial
Rules designed around genetically modified plants crops are holding back new cell and gene-based medicines
-
FeatureThe long road to an HIV vaccine
A vaccine may not be available anytime soon, but its proponents are hard at work
-
BusinessAstraZeneca shares tumble after antibody failure
Imfinzi and tremelimumab checkpoint inhibitor pairing fails to beat chemotherapy in lung cancer
-
ResearchLilly pushes continuous drug production limits
Integrated flow synthesis and purification process for prexasertib meets high industry standards
-
OpinionUnpicking a clinical trial death
A new study shows up off-target effects of a drug that proved deadly, and highlights the pitfalls of drug discovery
-
OpinionHow safe should drugs be?
What does spotting new risks in approved medicines say about how effective regulators are?
-
ResearchCatalyst puts chiral twist on phosphorus drugs
Simple molecule overcomes headache of phosphorus stereochemistry in antiviral drug synthesis
-
NewsFears that gene-editing cancer trials are premature
Warnings from geneticists that Crispr trial failures could knock promising technique’s prospects
-
OpinionRegulatory tightropes
When lobbying and marketing clash with scientific evidence, regulators walk a fine line